What Happens Between Pre-Authorisation and the Invoice?

The visibility gap no insurer is talking about

Most insurers have a fairly clear process at the beginning of a high-cost case. The member submits documents, the diagnosis is reviewed, the treatment plan is assessed, the hospital shares an estimate, and the claims or medical team checks whether the member is covered and whether the proposed treatment and cost are reasonable. If everything looks in order, the case is approved and, where required, a guarantee of payment is issued. At that point, the case feels controlled.

There is an approved diagnosis, an approved treatment plan, an approved provider and an expected cost. In many organisations, that is also the point where the intensity of scrutiny begins to reduce.

The assumption is that the patient will now go through treatment more or less as planned and the next major financial event will be the final invoice.

The most important part of the case often begins after approval

In reality, healthcare rarely follows the quotation exactly as approved. A patient expected to remain admitted for five days may stay for nine. Further investigations may alter the treatment plan. An implant that was not part of the original estimate may be introduced. A complication may require ICU admission. Another specialist may become involved, or the hospital may ask for an additional guarantee of payment.

None of these events automatically means that something improper has happened. Clinical circumstances change, and sometimes those changes are entirely justified. The issue is whether the insurer knows about them early enough to understand the clinical and financial implications. If the payer only learns about the change after discharge, the opportunity to influence the case has already narrowed significantly.

Where visibility starts to fragment

This problem becomes particularly visible in international healthcare. Once the member travels overseas, the case can be distributed across the hospital, the TPA, the assistance company, the broker, the treating doctor, the claims team and sometimes an agent or facilitator. One party has the clinical update, another has the approval, another is communicating with the family and another is handling the invoice.

Emails are exchanged, WhatsApp messages are sent, additional reports arrive and the treatment continues. Everyone may be doing their job, but nobody necessarily has a complete view of the case. That is the visibility gap: the period between what the insurer originally authorised and what eventually appears on the final invoice. In many high-cost cases, it is also the most financially sensitive part of the entire journey.

A quotation is not a controlled budget

One of the easiest assumptions to make in a high-cost medical case is that an approved hospital quotation has effectively become the case budget. It has not. A quotation is only an estimate based on what is expected to happen before treatment begins. The actual exposure depends on what happens afterwards.

Length of stay may change. Procedures may change. Complications may occur. Additional consumables may be used. New clinical decisions may be made. The insurer therefore needs to ask more than whether the original treatment was approved. It needs to know whether the case is still following the pathway that was approved and whether the financial exposure is changing while the patient is still under treatment.

Why the final invoice is often too late

Too often, the full picture becomes clear only when the invoice reaches the claims team. Additional hospital days appear. There may be ICU charges that were not expected, a more expensive implant, extra consultations, additional medicines or a second procedure. Sometimes the hospital has already requested one or more extensions to the original guarantee of payment, but the overall impact is only understood after discharge.

At that point, the insurer can still ask questions. It can request records, dispute unsupported charges and negotiate certain items. But the clinical event has already happened and the cost has already been incurred. The strongest opportunity to influence the case was earlier, while treatment was still in progress.

High-cost care needs continuous governance, not two checkpoints

This is why claims control cannot begin and end with pre-authorisation and invoice review. High-cost healthcare needs to remain governed throughout the journey. The insurer should be able to compare, at any point, what was authorised, what is actually happening and what is eventually being charged.

What was authorised may include the diagnosis, procedure, provider, expected length of stay and approved financial exposure. What is actually happening may include the real procedure performed, the actual length of stay, complications, treatment changes and additional approvals. The final invoice then needs to be reconciled against both. When these three views are connected, the case stops being a transaction moving from approval to payment. It becomes a clinical journey that remains financially governed throughout.

International care makes the gap harder to ignore

The visibility problem becomes even more important when treatment takes place in another country. The insurer may be operating thousands of kilometres away from the treating provider, across different health systems, currencies, time zones and clinical practices. Once the member crosses the border, the payer can become increasingly dependent on whichever party happens to be closest to the patient.

International healthcare therefore requires more control, not less. The important questions are not only whether the member is covered or whether the hospital estimate is within the policy limit. The insurer should also be asking whether overseas treatment was necessary in the first place, whether the chosen provider and destination were appropriate, whether the expected cost was reasonable, whether the patient is staying longer than anticipated, whether the treatment has materially changed and whether the case needs to return for another clinical or financial decision.

Closing the gap with MediGence CCP (Controlled Care Pathways)

This is one of the problems MediGence is addressing through CCP - Controlled Care Pathways. The idea is not to replace the insurer's existing TPA, hospital network or a broker. Those relationships can continue to operate as they do today. The role of CCP is to create a structured control layer around the journey.

Before financial commitment, the focus is on policy eligibility, clinical necessity, provider and destination selection, expected cost and risk. During treatment, the focus shifts to visibility: length of stay, treatment changes, additional procedures, budget deviation and escalation. After discharge, the insurer can reconcile what was authorised with what was actually delivered and what was ultimately invoiced.

The larger point is that the future of claims control will not be determined only by how quickly insurers process an invoice. The bigger opportunity is to improve the quality of the decisions that happen before the invoice exists. By the time the final bill reaches the claims team, some of the most important clinical and financial decisions may already be irreversible.

The real question for insurers

For insurers managing high-cost or international healthcare, the period between approval and payment should not be treated as a blind spot. It should be one of the most closely governed parts of the entire case. The question is no longer simply whether a treatment was approved.

The more important question is whether the insurer remained in control of what happened after approval - clinically, operationally and financially.